Biohaven Ltd. 8-K

What Happened

• Biohaven Ltd. filed an 8‑K on January 6, 2026, announcing it agreed to issue and sell 12,500,000 common shares to Janus Henderson Investors at $10.00 per share. The company expects to receive $125 million in gross proceeds upon settlement, before fees and other expenses.
• The shares are being sold as a block transaction under Biohaven’s registered “at‑the‑market” (ATM) offering program (registration statement on Form S-3, File No. 333-274822). The ATM terms are described in the prospectus supplement dated August 16, 2024. The filing was signed by CFO Matthew Buten.

Key Details

• Number of shares: 12,500,000 common shares.
• Price per share: $10.00.
• Gross proceeds expected: $125,000,000 (before fees and expenses).
• Transaction date/filed: Agreement announced January 6, 2026; offering registered under Form S-3 (File No. 333-274822); prospectus supplement dated August 16, 2024.

Why It Matters

• This transaction will raise immediate capital for Biohaven, increasing cash on hand by roughly $125 million before costs. That can support operations, R&D, or other corporate needs (the filing does not specify use of proceeds).
• Issuing 12.5 million new shares increases the company’s outstanding share count and will have a dilutive effect on existing shareholders; investors should monitor updated share counts and any further disclosures about use of proceeds or share issuance timing.